Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024  - Episode 10

Safety Profile of Available Frontline Treatments LR-MDS

, , , ,

Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    • Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS.
    • How would you mitigate those events in your practice?
    • How does toxicities observedimpact your overall treatment selection for patients?
    x